Opinion|Videos|March 17, 2025
Episode 3 Video: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges
Author(s)Wayne Kuang, MD, Matt T. Rosenberg, MD
Wayne Kuang, MD; and Matt T. Rosenberg, MD, discuss how overactive bladder presents with distinct pathophysiological mechanisms between genders, requires different diagnostic approaches when distinguishing from benign prostatic hyperplasia in men, impacts quality of life in older adults, benefits from early primary care intervention, and necessitates improved patient advocacy and educational initiatives for optimal management outcomes.
Advertisement
Episodes in this series
Notes:
0:00-9:35 Dual Diagnosis: OAB and BPH
9:36-13:10 Understanding Symptoms of OAB
13:11-17:25 Managing OAB
17:26-28:44 Treatment Options for OAB
28:45-35:08 Role of Primary Care Providers
35:09-41:37 Educational Outreach in OAB
Advertisement
Related to this article
Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.
This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.
Take a look through some of the notable data presentations at this year's ESMO Congress.
The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
The agency issued a PDUFA target action date of June 14, 2027.
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Advertisement
Advertisement
Trending on Urology Times
1
Michael Cookson, MD, reacts to Anktiva’s expanded approval in NMIBC
2
FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC
3
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
4
ESMO 2026: Key presentations across genitourinary oncology
5